Dendritic Cell-based Immunotherapy (DCVAC/OvCa) Combined with Second-line Chemotherapy in Platinum-sensitive Ovarian Cancer (SOV02): A Randomized, Open-label, Phase 2 Trial

CIBULA, D., ROB, L., MALLMANN, P., KNAPP, P., KLAT, J., CHOVANEC, J., MINÁŘ, L., MELICHAR, B., HEIN, A., KIESZKO, D., PLUTA, M., ŠPAČEK, J., BARTOŠ, P., WIMBERGER, P., MADRY, R., MARKOWSKA, J., STREB, J., VALHA, P., BIN HASSAN, H. I., PECEN, Ladislav, GALLUZZI, L., FUČÍKOVÁ, J., HRNČIAROVÁ, T., HRAŠKA, M., BARTŮŇKOVÁ, J., SPÍŠEK, R. Dendritic Cell-based Immunotherapy (DCVAC/OvCa) Combined with Second-line Chemotherapy in Platinum-sensitive Ovarian Cancer (SOV02): A Randomized, Open-label, Phase 2 Trial. Gynecologic Oncology. 2021, 162(3), 652-660. ISSN 0090-8258. E-ISSN 1095-6859. Dostupné z: doi: 10.1016/j.ygyno.2021.07.003.